Parabolic Drugs Ltd.
NSE: PARABDRUGS | BSE: 533211
₹5.50
₹-0.25
(-4.35%)
As on 25-Jan-2021IST
Market cap
₹35 Cr
Revenue (TTM)
₹0 Cr
P/E Ratio
--
P/B Ratio
-0
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹-20 Cr
-
ROE
0 %
-
ROCE
-32 %
-
Industry P/E
40.16
-
EV/EBITDA
-283.2
-
Debt to Equity
-1.1
-
Book Value
₹--
-
EPS
₹-3.2
-
Face value
10
-
Shares outstanding
61,892,014
10 Years Aggregate
CFO
₹145.72 Cr
EBITDA
₹-424.10 Cr
Net Profit
₹-1,148.47 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Parabolic Drugs
| 8.9 | 29.4 | 120.0 | 254.8 | -12.5 | -7.1 | -20.3 |
|
BSE Sensex*
| -8.8 | 1.5 | 1.6 | -4.4 | 6.0 | 6.7 | 10.8 |
|
BSE Healthcare#
| 18.0 | 3.7 | 8.0 | 16.2 | 22.8 | 14.9 | 12.3 |
|
Company
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
2014
|
|---|---|---|---|---|---|---|---|
|
Parabolic Drugs
| 77.2 | 15.4 | -70.6 | 6.3 | -26.6 | -0.5 | 19.6 |
|
BSE Sensex
| 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 | 29.9 |
|
BSE Healthcare
| 61.4 | -3.5 | -5.9 | 0.5 | -12.9 | 15.1 | 47.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Parabolic Drugs
|
5.5 | 35.3 | 0.0 | -20.0 | -- | -- | -- | 0.0 |
| 3,314.3 | 27,186.1 | 1,461.8 | 387.4 | 34.5 | 25.2 | 70.4 | 15.7 | |
| 844.4 | 16,236.1 | 7,784.0 | 688.5 | 10.6 | 14 | 23.4 | 2.8 | |
| 458.5 | 17,459.8 | 2,141.5 | 58.5 | 5.8 | 3.3 | 164.4 | 4.5 | |
| 832.0 | 20,475.5 | 5,632.3 | 662.4 | 17.2 | 14.3 | 30.9 | 4.2 | |
| 1,542.0 | 17,217.6 | 1,543.3 | -48.6 | 3.6 | -0.6 | -- | 2.9 | |
| 212.5 | 28,284.5 | 9,205.3 | -371.8 | 1.7 | -3.8 | -- | 3.5 | |
| 1,865.0 | 29,986.1 | 1,935.8 | 288.2 | 20.6 | 29.8 | 104 | 22.3 | |
| 413.0 | 16,681.6 | 3,600.2 | 221.0 | 9.7 | 5.6 | 75.5 | 3.5 | |
| 1,896.8 | 30,609.5 | 3,564.0 | 414.0 | 15.3 | 8.4 | 74.8 | 6.1 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Parabolic Drugs
Manufacture of pharmaceuticals, medicinal chemical and botanical products
-
Incorporated
1996
-
Chairman
--
-
Managing Director
Pranav Gupta
-
Headquarters
Chandigarh, Union Territory
-
Website
Looking for more details about Parabolic Drugs Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Parabolic Drugs
What is the current share price of Parabolic Drugs Ltd Today?
The share price of Parabolic Drugs Ltd is ₹5.50 (NSE) and ₹5.70 (BSE) as of 25-Jan-2021 IST. Parabolic Drugs Ltd has given a return of -12.46% in the last 3 years.
What is the current PB & PE ratio of Parabolic Drugs Ltd?
Since, TTM earnings of Parabolic Drugs Ltd is negative, P/E ratio is not available.
The P/B ratio of Parabolic Drugs Ltd is -0.04 times as on 25-Jan-2021, a 101 discount to its peers’ median range of 4.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2018 |
0.00 |
-0.05 |
2017 |
0.00 |
-0.06 |
2016 |
0.00 |
-0.04 |
2015 |
0.00 |
-0.18 |
2014 |
0.00 |
2.19 |
What is the 52 Week High and Low of Parabolic Drugs Ltd?
The 52-week high and low of Parabolic Drugs Ltd are Rs -- and Rs -- as of 27-Aug-2026.
What is the market cap of Parabolic Drugs Ltd?
Parabolic Drugs Ltd has a market capitalisation of ₹ 35 Cr as on 25-Jan-2021. As per SEBI classification, it is a company.
Should I invest in Parabolic Drugs Ltd?
Before investing in Parabolic Drugs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.